MedTrace Logo

Methotrexate Versus Secukinumab Safety in Psoriasis Patients With Metabolic Syndrome

NCT04469829 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 70

Last updated 2020-07-14

No results posted yet for this study

Summary

A prospective, controlled, open trial in psoriasis patients with metabolic syndrome, candidate to methotrexate or secukinumab was conducted between January 2019 and May 2020. The primary end point of the study was investigating any variations in waist circumference, body mass index (BMI), blood pressure, fasting glucose, total cholesterol, low density lipoprotein (LDL)-cholesterol, high density lipoprotein (HDL)-cholesterol, triglycerides, aspartate aminotransferase (AST), alanine aminotransferase (ALT), creatinine levels between baseline and month-6 and 12 of follow-up.

Conditions

Interventions

DRUG

Secukinumab

standard doses of secukinumab for psoriasis

DRUG

Methotrexate

Methotrexate 15 mg/week

Sponsors & Collaborators

  • Universita di Verona

    lead OTHER

Principal Investigators

  • Paolo Gisondi, MD · Universita di Verona

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-08-01
Primary Completion
2021-12-31
Completion
2022-12-31

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04469829 on ClinicalTrials.gov